TP53 and cancer: Similar effects of this compound on radiation-induced cell death have been seen in models of typically radio-resistant cancer, such as pontine glioma,18 glioblastoma19 and pancreatic adenocarcinoma.20 Importantly, one study has shown that WEE1 inhibition by AZD1775 sensitises acute myelogenous leukaemia and lung cancer cell lines to cytarabine chemotherapy independently of p53 status,10 suggesting that p53 mutation as a predictive biomarker for response to WEE1 inhibition may be cancer and/or chemotherapy specific.